Post

New research · Internal Medicine
Current oncology (Toronto, Ont.) · 3h
Systematic reviewCurrent oncology (Toronto, Ont.) · 2026

Predictors and Risk Assessment Models for Venous Thromboembolism in Patients Diagnosed with Lymphoma: A Systematic Review.

Anca Maria Pop, Markus Rütti
Read paper
Internal MedicineSystematic review

Venous thromboembolism occurs in 4-12% of patients with lymphoma.

Predictors and Risk Assessment Models for Venous Thromboembolism in Patients Diagnosed with Lymphoma: A Systematic Review.

Anca Maria Pop, Markus Rütti
Current oncology (Toronto, Ont.) · 2026
Purpose

The aim of this systematic review was to summarize the evidence regarding predictors and available risk assessment models (risk assessment models) for venous thromboembolism in patients with lymphoma.

Results
4-12%
up to 1 in 8 lymphoma patients develop a blood clot
n = 44 studies
More results

Although Khorana score was validated for stratifying venous thromboembolism risk in cancer, its discrimination reliability in lymphoma is reduced by the lack of specific predictors.

Out of 592 evaluated papers, 44 met the inclusion criteria.

More results

The widely used Khorana score failed to appropriately identify patients with lymphoma at high risk for venous thromboembolism, while the Thrombosis Lymphoma predictive score (ThroLy) showed modest improvement.

“
Conclusion

Therefore, larger studies with external validation cohorts are needed to design lymphoma-specific risk assessment models and to identify predictors with high discrimination power.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
13.5%
Central retinal artery peak blood-flow speed was 13.5% lower in diabetic patients.
Cohort Study
4.5 minutes
Each visual-field test averaged 4.5 minutes per eye.
Review
46.7%
nearly half of thyroid patients had Graves' disease, the most common overactive-thyroid condition
Cross-sectional
MYR 88,346.12
Average annual out-of-pocket expenditure for patients with cancer in Malaysia.
Case-control
5.4% Reduction in Odds of Neuropathy
each rise in zinc levels lowers the chance of nerve damage
Cross-sectional
SIR 9.93
risk climbs sharply when relatives cluster and clotting starts young
Cohort Study
67.8%
one-year survival was far worse than the intermediate-risk group's, roughly one in three died
Systematic Review
“Current evidence does not support universal thromboprophylaxis following ACLR.”